Phathom Pharmaceuticals, Inc. (PHAT)
5.74
-0.48
(-7.72%)
USD |
NASDAQ |
Oct 30, 16:00
5.85
+0.11
(+1.92%)
After-Hours: 20:00
Phathom Pharmaceuticals Enterprise Value : 837.11M for Oct. 30, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 30, 2026 | 837.11M |
| October 29, 2026 | 876.10M |
| October 28, 2026 | 880.97M |
| October 27, 2026 | 857.42M |
| October 26, 2026 | 853.36M |
| October 23, 2026 | 837.11M |
| October 22, 2026 | 940.26M |
| October 21, 2026 | 941.89M |
| October 20, 2026 | 964.63M |
| October 19, 2026 | 940.26M |
| October 16, 2026 | 932.95M |
| October 15, 2026 | 980.06M |
| October 14, 2026 | 971.94M |
| October 13, 2026 | 939.45M |
| October 12, 2026 | 950.01M |
| October 09, 2026 | 959.76M |
| October 08, 2026 | 950.01M |
| October 07, 2026 | 924.02M |
| October 06, 2026 | 921.58M |
| October 05, 2026 | 915.09M |
| October 02, 2026 | 932.95M |
| October 01, 2026 | 945.95M |
| September 30, 2026 | 963.82M |
| September 29, 2026 | 958.86M |
| September 28, 2026 | 958.06M |
| Date | Value |
|---|---|
| September 25, 2026 | 954.06M |
| September 24, 2026 | 936.44M |
| September 23, 2026 | 928.84M |
| September 22, 2026 | 990.89M |
| September 21, 2026 | 966.07M |
| September 18, 2026 | 968.47M |
| September 17, 2026 | 990.09M |
| September 16, 2026 | 985.28M |
| September 15, 2026 | 1.023B |
| September 14, 2026 | 1.065B |
| September 11, 2026 | 1.039B |
| September 10, 2026 | 1.040B |
| September 09, 2026 | 1.064B |
| September 08, 2026 | 1.125B |
| September 04, 2026 | 1.130B |
| September 03, 2026 | 1.094B |
| September 02, 2026 | 1.111B |
| September 01, 2026 | 1.121B |
| August 31, 2026 | 1.136B |
| August 28, 2026 | 1.105B |
| August 27, 2026 | 1.085B |
| August 26, 2026 | 1.072B |
| August 25, 2026 | 1.074B |
| August 24, 2026 | 1.063B |
| August 21, 2026 | 1.080B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.889B |
| Corcept Therapeutics, Inc. | 8.456B |
| Veru, Inc. | 14.23M |
| Johnson & Johnson | 685.05B |
| Eli Lilly & Co. | 1.379T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.90M |
| Revenue (Quarterly) | 84.72M |
| Total Expenses (Quarterly) | 98.62M |
| EPS Diluted (Quarterly) | -0.1637 |
| Gross Profit Margin (Quarterly) | 78.32% |
| Profit Margin (Quarterly) | -16.40% |
| Earnings Yield | -17.95% |
| Normalized Earnings Yield | -17.95 |